Oxaliplatin-related side effects: characteristics and management.
about
Studies on anticancer activities of antimicrobial peptidesSystemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and managementReview of systemic therapies for locally advanced and metastatic rectal cancerManagement of locally advanced and metastatic colon cancer in elderly patientsOxaliplatin-Induced Peripheral Neuropathy via TRPA1 Stimulation in Mice Dorsal Root Ganglion Is Correlated with Aluminum AccumulationMembrane transporters as mediators of Cisplatin effects and side effects.Hemolytic uremic syndrome following the infusion of oxaliplatin: case report.Toxicities of the platinum antineoplastic agents.Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.Oxaliplatin-induced acute thrombocytopenia.Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin.Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.A novel behavioral assay for measuring cold sensation in mice.Nanocarriers for delivery of platinum anticancer drugs.Oxaliplatin-Related Ocular ToxicityPhase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer.Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.Neurotoxicity caused by the treatment with platinum analogues.Molecular mechanisms of resistance and toxicity associated with platinating agents.L type Ca²+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in ratsA review of oxaliplatin and its clinical use in colorectal cancer.The clinical analysis of acute pancreatitis in colorectal cancer patients undergoing chemotherapy after operation.Preparation and In Vivo Evaluation of Dichloro(1,2-Diaminocyclohexane)platinum(II)-Loaded Core Cross-Linked Polymer MicellesLaser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study.Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis.Aqueous extract of Lithospermi radix attenuates oxaliplatin-induced neurotoxicity in both in vitro and in vivo modelsUFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancerOxaliplatin-DNA adduct formation in white blood cells of cancer patientsOxaliplatin in the treatment of colorectal cancer.Metastatic colorectal cancer-past, progress and futureConus vexillum venom induces oxidative stress in Ehrlich's ascites carcinoma cells: an insight into the mechanism of induction.Assessment of nerve excitability in toxic and metabolic neuropathies.Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.Sarcoidosis associated with oxaliplatin-based chemotherapy for colorectal cancer.Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs.Acute pain associated with oxaliplatin infusion: case report and literature review.Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent.
P2860
Q24650885-A438DEFD-53CE-4435-B765-AFBF0C833C52Q26830695-FE74FD5C-B079-41B5-9A54-84A0910C47B0Q27021105-3C210916-8D2C-4611-A8A7-02613D0682B7Q27026129-1589CD9E-866F-46AE-B7D9-8515BE4E2A0FQ28546867-E02B1B7B-29CD-4DA4-8AB9-6C63E16EFDF3Q30446860-96159B90-2F96-496E-AF5D-6E51090D9159Q33257302-6AC30673-F665-4954-8BFA-0FCC553B3237Q33357351-3CF14619-2731-403F-AEAC-744BFAC18F55Q33361500-01AED4F1-CF97-4561-A632-79CD2EA6C856Q33373035-D4E48A4B-4124-41F7-B8E7-60FDE5829C06Q33391330-AF1C8EAB-86DE-4BF0-93B9-0E57ABAA0B39Q33397057-EE6F9B6F-6D04-46F5-A96F-74BD98C4B53EQ33400418-B4D7FDFA-5B73-4B99-9102-0348C0265732Q33873552-5D464066-DD64-440A-A7BD-9CA1B432A27CQ34321665-6F1683D6-F02E-46C8-AA22-590B0CE0C4C2Q34338695-4B0E2F23-6F4F-49B5-9CA6-0556E57546B7Q34394155-4A9A41E1-1330-4F63-9E2A-CE277CCAD16CQ34611822-22D2C1B7-8E30-4503-9AC0-83830AE90321Q35103028-E3692595-B941-48BB-9D44-93291063F16DQ35598162-7690A708-E9CA-4D97-A1D3-9805250B1CF9Q35692169-7D80BFE7-AE44-40C2-8EDC-2020A1C012F2Q35758048-55C40DC1-926D-4954-9D1F-A95A64E7172AQ35772998-CF9DB383-EB37-4C57-B857-D72587F40B74Q35906940-538E22EC-5BC1-4637-A3E7-BDC0FD2373B7Q36072532-17EEA397-56FD-441A-94C8-536F8EA210A7Q36111392-909FD698-73A5-4DC9-A79A-3B05AB1093FFQ36129089-FC70D767-2667-4707-8972-710606C68F88Q36159222-01F3055C-9272-4793-836D-B92AF0C7AE34Q36174729-53D45264-85B3-47D7-8C1F-36AB8A217A72Q36694455-9BF4DCB4-9C83-4CE9-BE39-CD337D937BAEQ36740632-9916D8D2-47EA-45A3-8436-00CDCA36C537Q36788436-DBB34BAC-B00B-4C66-BB76-4D699307336EQ36893806-75639D72-7B95-49FF-B6FF-09748FA85702Q37008334-2E3C1871-FFBD-46B7-A983-6DFDC4DE03A3Q37111987-81FECFC7-4273-4A9E-A543-9B758289DABBQ37118923-68CBEC78-1E1F-4E5C-B0FE-D7CF19768DBAQ37673380-89A210D0-1F1F-4286-B3CB-4593416E2C80Q37938364-C704EC72-6499-4C87-8987-66774C6A9861Q37955698-257CBD71-740E-4C27-AFCD-900E9901F476Q37983953-BACD2E9E-56FA-4871-B491-216231B6D31C
P2860
Oxaliplatin-related side effects: characteristics and management.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Oxaliplatin-related side effects: characteristics and management.
@ast
Oxaliplatin-related side effects: characteristics and management.
@en
type
label
Oxaliplatin-related side effects: characteristics and management.
@ast
Oxaliplatin-related side effects: characteristics and management.
@en
prefLabel
Oxaliplatin-related side effects: characteristics and management.
@ast
Oxaliplatin-related side effects: characteristics and management.
@en
P356
P1433
P1476
Oxaliplatin-related side effects: characteristics and management.
@en
P2093
Jean-Louis Misset
Jim Cassidy
P356
10.1053/SONC.2002.35524
P433
5 Suppl 15
P577
2002-10-01T00:00:00Z